Physician profile
Marc Vala
NPI 1386685394
$779.51
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $94.82 · 2022: $90.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $204.16 | 2019-2020 | |
| Celgene Corporation | $139.20 | 2019 | |
| Eisai INC. | $109.10 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $90.90 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.44 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $48.88 | 2019-2020 | |
| Puma Biotechnology, INC. | $46.18 | 2019 | |
| Stemline Therapeutics INC. | $31.80 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $29.78 | 2019 | |
| Seagen INC. | $13.65 | 2019 | |
| Aurobindo Pharma USA, INC. | $11.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Vala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.